Physician profile
Jack Holladay
NPI 1851321277
$1,184,613.83
in general payments reported to CMS, 2019-2025
11 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216K · 2020: $76K · 2021: $198K · 2022: $273K · 2023: $276K · 2024: $37K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $231K · Consulting Fee: $108K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $231,400.00 |
| Consulting Fee | $107,830.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,508.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Ag | $658,460.00 | 2019-2023 | Iolmaster 500 |
| Oculus, INC. | $240,000.00 | 2019-2025 | Pentacam |
| Carl Zeiss Meditec Digital Innovations LLC | $103,675.00 | 2019-2023 | Veracity Surgical |
| Rxsight INC | $81,508.83 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Alcon Research LLC | $33,250.00 | 2019 | |
| Heidelberg Engineering, INC. | $27,720.00 | 2021-2025 | Spectralis |
| Johnson & Johnson Surgical Vision, INC. | $25,000.00 | 2019 | |
| Haag-Streit USA, INC. | $10,000.00 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $3,000.00 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $2,000.00 | 2023-2025 | Stellaris Elite |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$353,538.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Holladay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.